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In the last decade, chemotherapy (CT) has shown 
a significant reduction of morbidity and mortality of the 
hematooncologic patients. However, the beneficial ef-
fects of this therapy can be limited by the development 
of acute or chronic cardiotoxicity, and the early detec-
tion of cardiotoxicity due to CT is a critical issue in the 
clinical setting [1]. Various methods are recommended 
to diagnose cardiotoxicity, such as electrocardiogra-
phy or the evaluation of biochemical markers [2, 3]. In 
process of time, echocardiography has emerged as 
the most useful test of the non-invasive detection of 
cardiotoxicity [4]. Echocardiography allows identifying 
the early markers of the systolic and diastolic left ven-
tricular (LV) dysfunction. Silent diastolic dysfunction is 
considered to be the first manifestation of the cardiac 
related toxicity and is followed by systolic dysfunction 
[5]. In our pilot study, we have used the serial of Doppler 
echocardiografic measurements to analyze the very 
early changes of diastolic LV function during and after 
CT in patients with newly diagnosed acute leukemia. 
Twenty-six consecutive patients (15 males, 11 fe-
males, mean age of 46.2 ± 12.4 yrs, range: 22–61 yrs), 
with acute leukemia have been studied. Seven patients 
were treated for arterial hypertension. Renal and liver 
functions were normal in all patients. No patient has 
been treated with CT or radiotherapy previously. The 
patients have been given 2–6 cycles of conventional 
CT containing anthracycline agent in the total cumu-
lative dose of 464.3 ± 117.5 mg m–2 (range: 240–715, 
median 425.5). To calculate the total cumulative dose 
of anthracyclines, we have applied the conversion 
factors derived from the maximum recommended cu-
mulative doses for individual agents used (idarubicine, 
daunorubicine, mitoxantrone). Cardioprotection with 
dexrazoxane hasn’t been used. Afterwards, sixteen 
patients have undergone the preparative regimen and 
hematopoietic cell transplantation within two months 
after the completion of CT. The local ethical committee 
approved the study protocol. All patients provided a 
written consent before they were included in the study. 
The cardiac evaluation was performed at the baseline 
(before CT), after the first CT (mean cumulative an-
thracyclines dose 136.3 ± 28.3 mg m–2), after the last 
CT (mean cumulative anthracyclines dose 464.3 ± 
117.5 mg m–2) and circa 6 months after the completion 
of CT (range: 5–8 months, median 6.0). The ECHO 
evaluation was performed on Hewlett Packard Image 
Point machine. The parameters of the systolic and 
the diastolic LV function and the presence of pericar-
dial effusion were assessed. The systolic LV function 
was assessed using LV ejection fraction (LVEF) and 
fractional shortening (FS). To evaluate diastolic LV 
function, we used the major pulsed-wave Doppler in-
dexes of impaired diastolic function: E/A ratio, E-wave 
deceleration time (DT) and isovolumic relaxation time 
of the left ventricle (IVRT). The diastolic LV dysfunction 
was defined as E/A inversion and DT-E above 220 ms 
on the transmitral Doppler curve (impaired relaxation). 
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Pericardial effusion was defined as the separation of 
pericardial leaves at least 2 mm in systole. The statis-
tical analysis was performed with the “Statistica for 
Windows, Version 5.0” program. The analysis of the 
variance test was used. The values are expressed as 
mean ± SD. The probability value (p) < 0.01 was con-
sidered statistically significant. 
During the six-month follow-up, we found a signifi-
cant decrease in LVEF (65.3 ± 4.5% vs 60.2 ± 5.7%, 
p < 0.01), the fractional shortening of the LV (34.8 ± 
3.7%, vs 29.5 ± 5.0%, p < 0.01), but the mitral flow 
rapid filling velocity (E-wave) was not changed (0.74 ± 
0.18 ms–1, vs 0.67 ± 0.17 ms–1, p ns), and atrial filling 
velocity (A-wave) increased (0.66 ± 0.15 ms–1 vs 0.78 ± 
0.18 ms–1, p < 0.01). Therefore, E/A ratio significantly 
decreased (1.18 ± 0.35 vs 0.89 ± 0.27, p < 0.01). IVRT 
increased (71.5 ± 11.6 ms vs 84.0 ± 11.6 ms, p < 0.01). 
DT E-wave velocity increased (162.3 ± 25.8 ms vs 
206.7 ± 25.5 ms, p < 0.01). During the 6-month follow-
up, there were no significant changes in left atrium, 
right ventricular, left ventricular end-systolic and 
end-diastolic diameters. After the first CT, the signs 
of LV diastolic dysfunction were detected in 5 (19.2%) 
patients. 6 months after the last CT, two of these pa-
tients (7.7%) developed LV systolic dysfunction with 
the clinical symptoms of heart failure. Six months after 
the last CT, 12 (46.2%) patients developed the signs 
of LV diastolic dysfunction.
As the anthracycline-induced cardiotoxicity is 
largely irreversible, it is crucial to detect the myocardial 
injury at its earliest possible stage [6, 7]. However, the 
parameters of the systolic function of the left ventricle 
(EF and FS) are not very sensitive to diagnose the 
subclinical forms of cardiotoxicity. Therefore, Dop-
pler derived diastolic indexes are recognized as early 
signs of the left ventricular dysfunction in patients 
undergoing CT [4].
In our study, we have showed that the first changes 
in diastolic LV function could develop even in a few 
weeks after starting of CT. We have found the signifi-
cant changes of Doppler derived echocardiographic 
diastolic parameters of the left ventricle — the signifi-
cant decrease of E/A ratio, prolongation of DT of the 
E-velocity and IVRT. We have also found the decrease 
of the systolic LV parameters — EF and FS. 
The diagnostic role of Doppler echocardiography 
to detect cardiotoxicity after anthracycline therapy 
was studied previously. Krupicka et al. [8] investigated 
possible acute effects in 88 patients with Hodgkin’s 
lymphoma who did not show the significant changes 
of M-mode derived LV end-diastolic diameter, end-
systolic diameter and EF, but identified regional wall 
motion abnormalities (hypokinesis) by 2D assessment. 
The chronic cardiotoxicity is often manifested by LV 
dysfunction and heart failure, which may be detected 
by the monitoring of Doppler diastolic indexes earlier 
than by measurement of ejection fraction (EF) [9]. 
Early peak flow velocity to atrial peak flow velocity 
(E/A) ratio, deceleration time and isovolumic relaxation 
time were all impaired (grade I of diastolic dysfunction) 
in more than 50% of patients treated with anthracy-
clines, when EF was still normal. 
Compared to previous observations [6, 10–12], our 
study refers very early changes of the diastolic function 
of the left ventricle in patients undergoing anthracy-
cline chemotherapy. These changes are considered to 
be the risk factors for development of heart failure in 
the future and can develop very early after the start of 
the anthracycline treatment. Motivated by this experi-
ence, we consider using Doppler echocardiography 
as the election tool not only for baseline cardiologic 
screening but also for the monitoring of the earliest 
subclinical signs of cardiotoxicity in oncologic patients 
during and after CT.
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МОНИТОРИНГ РАННЕЙ ДИАСТОЛИЧЕСКОЙ ДИСФУНКЦИИ 
ЛЕВОГО ЖЕЛУДОЧКА У БОЛЬНЫХ ОСТРОЙ ЛЕЙКЕМИЕЙ, 
ПРОШЕДШИХ КУРС ЛЕЧЕНИЯ АНТРАЦИКЛИНАМИ
Цель: проанализировать ранние изменения диастолической функции левого желудочка (ЛЖ) во время проведения 
химиотерапии (ХТ) и после ХТ у больных с первичнодиагностированной острой лейкемией. Методы: обследованы 
26 больных с острой лейкемией. Эхокардиограммы снимали до ХТ, после первого курса ХТ (среднее значение суммарной 
дозы антрациклинов 136,3 ± 28,3 мг м-2), после окончания ХТ (среднее значение суммарной дозы антрациклинов 464,3 
± 117,5 мг м-2) и через 6 мес после завершения ХТ. Результаты: выявлено значительное уменьшение фракции выброса 
ЛВ (65,3 ± 4,5% против 60,2 ± 5,7%, p < 0,01), фракции укорочения диастолы ЛЖ (34,8 ± 3,7% против 29,5 ± 5,0%, 
p < 0,01). Скорость наполнения митрального потока (E-волна) не изменялась (0,74 ± 0,18 мс–1 против 0,67 ± 0,17 м с–1), и 
предсердная скорость наполнения (A-волна) повышалась (0,66 ± 0,15 мс–1 против 0,78 ± 0,18 мс–1, p < 0,01). Отношение 
E/A существенно уменьшалось (1,18 ± 0,35 против 0,89 ± 0,27, p < 0,01). Время изоволюметрического расслабления 
увеличивалось (71,5 ± 11,6 мс против 84,0 ± 11,6 мс, p < 0,01). Время замедления кровотока E-волны увеличивалось 
(162,3 ± 25,8 мс против 206,7 ± 25,5 мс, p < 0,01). После первого курса ХТ признаки диастолической  дисфункции ЛЖ 
выявлены у 5 (19,2%) больных. Через 6 мес после окончания ХТ у 2 больных (7,7%) развилась систолическая дисфункция 
ЛЖ с клиническими симптомами паралича сердца, а у 12 (46,2%) больных выявлены признаки диастолической дис-
функции ЛЖ. Выводы: ХТ может вызывать ранние изменения диастолической функции ЛЖ. Предлагается использовать 
эхокардиографию Допплера не только для предварительного скрининга, но и для мониторнига ранних субклинических 
признаков кардиотоксичности.
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